Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deucravacitinib (BMS-986165) in Moderate-to-Severe Plaque Psoriasis
NCT03624127Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of deucravacitinib in plaque psoriasis (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Static Physician's Global Assessment Score of 0 or 1 at 16 weeks and Psoriasis Area and Severity Index 75% Improvement at 16 weeks. Started Aug 2018; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT03624127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03624127.